Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 54.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -51.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ginkgo Bioworks Holdings was 54.70% per year. The lowest was -782.60% per year. And the median was -235.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ginkgo Bioworks Holdings 3-Year EBITDA Growth Rate Related Terms
MEX:DNA vs RZLT, EIKN, ARTV: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Ginkgo Bioworks Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginkgo Bioworks Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ginkgo Bioworks Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 54.70% mean?
Ginkgo Bioworks Holdings (MEX:DNA) has a 3-Year EBITDA Growth Rate of 54.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ginkgo Bioworks Holdings and its competitors. According to the industry distribution chart, Ginkgo Bioworks Holdings ranks #134 out of 1136 companies in the Biotechnology industry, placing it in the top 11.8%.
Is Ginkgo Bioworks Holdings' 3-Year EBITDA Growth Rate too high?
Ginkgo Bioworks Holdings' current 3-Year EBITDA Growth Rate is 54.70%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Ginkgo Bioworks Holdings' value of 54.70% is 268.4% above this industry median. Based on the distribution chart, Ginkgo Bioworks Holdings ranks #134 out of 1136 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 54/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' 3-Year EBITDA Growth Rate compare to RZLT and EIKN?
According to the Biotechnology industry distribution chart, Ginkgo Bioworks Holdings ranks #134 out of 1136 companies for 3-Year EBITDA Growth Rate. This places Ginkgo Bioworks Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. Ginkgo Bioworks Holdings' value of 54.70% is 268.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ginkgo Bioworks Holdings's current 3-Year EBITDA Growth Rate of 54.70% is 268.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ginkgo Bioworks Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginkgo Bioworks Holdings's current 3-Year EBITDA Growth Rate is 54.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings (MEX:DNA) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN149.41, compared to a current price of MXN170.00 — trading 13.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 54.70% and 268.4% above the Biotechnology industry median of 14.85. Ginkgo Bioworks Holdings' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (MEX:DNA), the current 3-Year EBITDA Growth Rate is 54.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginkgo Bioworks Holdings (MEX:DNA) Overvalued in 2026?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings stock appears to be overvalued.
The current stock price of MXN170.00 is trading 13.8% above its estimated GF Value™ of MXN149.41.
GuruFocus considers Ginkgo Bioworks Holdings to be Modestly Overvalued.
Key valuation signals for MEX:DNA:
3-Year EBITDA Growth Rate: 54.70%
GF Value™: MXN149.41 vs. price of MXN170.00 (13.8% above fair value)
Industry Position: 268.4% above the Biotechnology median (#134 of 1136)
No single metric tells the full story. See the MEX:DNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
54GF Score
Get the complete analysis for MEX:DNA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:DNA has been successfully added to your 
